2010
Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. The Lancet 2010, 376: 367-387. PMID: 20650518, PMCID: PMC4855280, DOI: 10.1016/s0140-6736(10)60829-x.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAnti-HIV AgentsAntipsychotic AgentsAntitubercular AgentsAntiviral AgentsBacterial InfectionsComorbidityCriminal LawDrug InteractionsDrug Resistance, BacterialEvidence-Based MedicineHepatitis, Viral, HumanHIV InfectionsHumansMedication AdherenceMental DisordersNarcoticsPrisonersSubstance-Related DisordersTuberculosisConceptsSubstance use disordersDrug usersAntiretroviral therapyViral hepatitisHIV treatmentHealth of HIVPharmacokinetic drug interactionsSubstance use comorbiditiesMedication-assisted therapyEvidence-based treatmentsDrug-resistant strainsHealth-related outcomesHealth service deliveryInfectious complicationsMultiple comorbiditiesHIV infectionPsychiatric comorbidityPoor adherenceClinical managementCardiovascular diseaseInadequate prescriptionCongregate settingsDrug interactionsComorbiditiesHIVTransmission of Drug-Susceptible and Drug-Resistant Tuberculosis and the Critical Importance of Airborne Infection Control in the Era of HIV Infection and Highly Active Antiretroviral Therapy Rollouts
Shenoi SV, Escombe AR, Friedland G. Transmission of Drug-Susceptible and Drug-Resistant Tuberculosis and the Critical Importance of Airborne Infection Control in the Era of HIV Infection and Highly Active Antiretroviral Therapy Rollouts. Clinical Infectious Diseases 2010, 50: s231-s237. PMID: 20397953, PMCID: PMC3029014, DOI: 10.1086/651496.Peer-Reviewed Original ResearchConceptsInfection control strategiesResource-limited settingsHIV infectionInfection controlActive antiretroviral therapy rolloutHuman immunodeficiency virus (HIV) infectionAntiretroviral therapy rolloutTransmission of drugDrug-resistant TBImmunodeficiency virus infectionDrug-resistant tuberculosisHealth care workersAirborne infection controlNosocomial transmissionTuberculosis careVirus infectionCare workersInfectionCurrent outbreakHigh rateTBPotential benefitsMorbidityHIVTuberculosisTiming of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy. New England Journal Of Medicine 2010, 362: 697-706. PMID: 20181971, PMCID: PMC3076221, DOI: 10.1056/nejmoa0905848.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-Retroviral AgentsAntitubercular AgentsCD4 Lymphocyte CountDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesHIVHIV InfectionsHumansKaplan-Meier EstimateMaleMiddle AgedPatient ComplianceRNA, ViralTuberculosisViral LoadYoung AdultConceptsSequential therapy groupHuman immunodeficiency virusAntiretroviral therapyRate of deathTuberculosis therapyHIV infectionDaily antiretroviral regimenIntegrated antiretroviral therapyIntegration of tuberculosisStandard tuberculosis therapyPositive sputum smearPrimary end pointSafety Monitoring CommitteeDiagnosis of tuberculosisAcid-fast bacilliTiming of initiationAntiretroviral regimenAdverse eventsHIV servicesImmunodeficiency virusAntiretroviral drugsSputum smearStudy groupPatientsCell count
2008
Attitudes toward needle-sharing and HIV transmission risk behavior among HIV+ injection drug users in clinical care
Norton WE, Amico KR, Fisher WA, Copenhaver MM, Kozal MJ, Cornman DH, Friedland G, Fisher JD. Attitudes toward needle-sharing and HIV transmission risk behavior among HIV+ injection drug users in clinical care. AIDS Care 2008, 20: 462-469. PMID: 18449824, DOI: 10.1080/09540120701867081.Peer-Reviewed Original ResearchConceptsHIV-positive injection drug usersInjection drug usersRisk reduction interventionsClinical careDrug usersInjection drug use accountsHIV transmission risk behaviorsIncident HIV infectionTransmission risk behaviorsDrug-resistant HIVClinical care settingsSpread of HIVLogistic regression modelsAntiretroviral therapyHIV infectionHIV transmissionCare settingsRisk behaviorsClinical settingPast monthNegative attitudesSignificant correlatesHIVInterventionConsiderable proportion
2006
Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments
Fiellin DA, Friedland GH, Gourevitch MN. Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments. Clinical Infectious Diseases 2006, 43: s173-s177. PMID: 17109303, DOI: 10.1086/508180.BooksConceptsOpioid agonist treatmentOpioid dependenceAgonist treatmentHuman immunodeficiency virus (HIV) transmissionBuprenorphine/naloxone combinationNeurobiological basisOpioid withdrawalBuprenorphine treatmentHIV infectionDecreased riskNaloxone combinationOpioid receptorsGeneral physiciansMedical disordersNew treatmentsMethadoneVirus transmissionBuprenorphineTreatmentMedicationsPatientsChronicInfectionIntracellular processesPhysicians
2005
Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction
Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O'Mara E. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005, 19: 1635-1641. PMID: 16184033, DOI: 10.1097/01.aids.0000183628.20041.f2.Peer-Reviewed Original ResearchConceptsOpiate withdrawalPharmacokinetic interactionsChronic methadone therapyDaily protease inhibitorEffect of atazanavirIsomers of methadonePlasma maximal concentrationPlasma trough concentrationsEffective antiretroviral treatmentRelevant pharmacokinetic interactionsSteady-state pharmacokineticsConcentration-time curveSubstance abuse treatmentHIV diseaseTrough concentrationsAntiretroviral treatmentHIV infectionMethadone therapyDaily administrationDosage adjustmentAntiretroviral drugsBioequivalence rangePharmacological interactionsPlasma concentrationsRelevant symptoms
2004
Utility of Tuberculosis Directly Observed Therapy Programs as Sites for Access to and Provision of Antiretroviral Therapy in Resource-Limited Countries
Friedland G, Karim S, Karim Q, Lalloo U, Jack C, Gandhi N, Sadr W. Utility of Tuberculosis Directly Observed Therapy Programs as Sites for Access to and Provision of Antiretroviral Therapy in Resource-Limited Countries. Clinical Infectious Diseases 2004, 38: s421-s428. PMID: 15156433, DOI: 10.1086/421407.Peer-Reviewed Original ResearchConceptsHIV infectionAntiretroviral therapyHuman immunodeficiency virus (HIV) infectionTherapy programHIV/AIDS careObserved therapy programActive antiretroviral therapyImmunodeficiency virus infectionImmune deficiency syndromeBurden of diseaseResource-limited countriesResource limited countriesHIV/AIDSHIV diseaseTuberculosis careDisease burdenDeficiency syndromeAIDS careVirus infectionTuberculosisInfectionMajor causeDiseaseTherapyInadequate access
2003
Human Immunodeficiency Virus Infection Prevention: Strategies for Clinicians
Schreibman T, Friedland G. Human Immunodeficiency Virus Infection Prevention: Strategies for Clinicians. Clinical Infectious Diseases 2003, 36: 1171-1176. PMID: 12715313, DOI: 10.1086/374359.Peer-Reviewed Original ResearchConceptsHIV infectionClinical practiceHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionNew HIV infectionsClinical care sitesPrevention-related activitiesClinical care settingsIntegration of preventionEffective prevention programsPublic health modelFuture prevention activitiesSpecific prevention effortsHIV diseaseVirus infectionCare settingsCare sitesBehavioral counselingClinical careMedical interventionsPrevention programsInfectionPrevention effortsHealth modelPrevention activities
2002
A Phase II Randomized Study of the Virologic and Immunologic Effect of Zidovudine + Stavudine versus Stavudine Alone and Zidovudine + Lamivudine in Patients with >300 CD4 Cells Who Were Antiretroviral Naive (ACTG 298)
Pollard RB, Tierney C, Havlir D, Tebas P, Fox L, Smeaton L, Richman D, Friedland GH. A Phase II Randomized Study of the Virologic and Immunologic Effect of Zidovudine + Stavudine versus Stavudine Alone and Zidovudine + Lamivudine in Patients with >300 CD4 Cells Who Were Antiretroviral Naive (ACTG 298). AIDS Research And Human Retroviruses 2002, 18: 699-704. PMID: 12167276, DOI: 10.1089/088922202760072311.Peer-Reviewed Original ResearchConceptsCD4 cell countStandard of careD4TViral loadWeek 12Copies/Cell countMedian baseline viral loadPhase II Randomized StudyD4T armDual nucleoside therapyAntiretroviral-naive patientsBaseline viral loadWeeks of monotherapyViral load reductionTreatment of patientsDevelopment of multidrugAntiretroviral-NaiveAntiviral suppressionNaive patientsCD4 cellsImmunologic effectsHIV infectionRandomized studyNucleoside therapyIncreasing drug users’ adherence to HIV treatment: results of a peer-driven intervention feasibility study
Broadhead RS, Heckathorn DD, Altice FL, van Hulst Y, Carbone M, Friedland GH, O’Connor P, Selwyn PA. Increasing drug users’ adherence to HIV treatment: results of a peer-driven intervention feasibility study. Social Science & Medicine 2002, 55: 235-246. PMID: 12144138, DOI: 10.1016/s0277-9536(01)00167-8.Peer-Reviewed Original ResearchConceptsActive drug usersDrug users' adherenceDrug usersDrug treatmentMedical carePrimary careIntervention feasibility studySocial support structuresHealth advocatesUser adherenceTreatment program staffPeer-driven interventionHIV diseaseHIV infectionPatient adherenceSix-month studyHIV treatmentPhysician referralClinical appointmentsHIV therapeuticsCarePositive behavioral changesAdherencePeer pressureTreatment
2001
Trust and the Acceptance of and Adherence to Antiretroviral Therapy
Altice F, Mostashari F, Friedland G. Trust and the Acceptance of and Adherence to Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 47-58. DOI: 10.1097/00126334-200109010-00008.Peer-Reviewed Original ResearchInjection drug usersAntiretroviral therapyPotent new therapyStandardized chart reviewSocial isolationDrugs of abuseAntiretroviral regimenHIV clinicChart reviewHIV infectionHIV medicationsObserved therapyCorrelates of acceptanceHealth beliefsClinical informationHealth locusNew therapiesSide effectsPharmacy reviewDrug usersHealth statusInfected prisonersAIDS incidenceTherapyTherapeutic agentsTrust and the Acceptance of and Adherence to Antiretroviral Therapy.
Altice FL, Mostashari F, Friedland GH. Trust and the Acceptance of and Adherence to Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 47. PMID: 11579277, DOI: 10.1097/00042560-200109010-00008.Peer-Reviewed Original ResearchConceptsInjection drug usersAntiretroviral therapyPotent new therapyStandardized chart reviewSocial isolationDrugs of abuseAntiretroviral regimenHIV clinicChart reviewHIV infectionHIV medicationsObserved therapyCorrelates of acceptanceHealth beliefsClinical informationHealth locusNew therapiesSide effectsPharmacy reviewDrug usersHealth statusInfected prisonersAIDS incidenceTherapyTherapeutic agents
2000
Interactions between methadone and medications used to treat HIV infection: a review.
Gourevitch M, Friedland G. Interactions between methadone and medications used to treat HIV infection: a review. Annals Of Global Health 2000, 67: 429-36. PMID: 11064494.Peer-Reviewed Original ResearchConceptsMetabolic enzyme inductionAntiretroviral regimensAntiretroviral therapyHIV infectionPharmacokinetic interactionsNarcotic withdrawalPharmacologic interactionsMedication interactionsSpecific HIVPharmacologic studiesOpiate dependenceSide effectsMedicationsElectronic databasesMethadoneClinical implicationsHIVAdditional publicationsEnzyme inductionFurther studiesHuman subjectsScientific meetingsCurrent understandingRegimensPharmacotherapy
1999
Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone
Altice F, Friedland G, Cooney E. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999, 13: 957-962. PMID: 10371177, DOI: 10.1097/00002030-199905280-00012.Peer-Reviewed Original ResearchConceptsPharmacokinetic interactionsOpiate withdrawalMethadone levelsWithdrawal symptomsChronic methadone maintenance therapyNon-nucleoside reverse transcriptase inhibitorSubstance abuseInitiation of therapyMethadone maintenance therapyOpiate withdrawal symptomsRetrospective chart reviewSignificant pharmacokinetic interactionsInjection drug usersReverse transcriptase inhibitorHIV therapeutic agentsAntiretroviral therapyMaintenance therapyMethadone doseChart reviewHIV diseaseHIV infectionIncreased doseTranscriptase inhibitorTherapeutic benefitPatientsTuberculosis and HIV infection
Buitrago M, Friedland G. Tuberculosis and HIV infection. Current Infectious Disease Reports 1999, 1: 105-109. PMID: 11095774, DOI: 10.1007/s11908-999-0017-3.ChaptersProphylaxis of tuberculosisExpert consensus panelAntituberculous regimensAntiretroviral medicationsHIV infectionImportant new recommendationsEquivalent efficacyDrug interactionsConsensus panelShort courseLarge-scale studiesTuberculosisProphylaxisRegimensRifampinTreatmentNew recommendationsMedicationsHIVRifabutinInfectionIndividuals
1997
Epidemiology of HIV Infection and AIDS
Altice F, Friedland G. Epidemiology of HIV Infection and AIDS. Disease Management And Health Outcomes 1997, 1: 304-322. DOI: 10.2165/00115677-199701060-00004.Peer-Reviewed Original ResearchReasons of raceResource-poor worldHIV/AIDS pandemicHIV infectionTreatment optionsHIV preventionNew therapiesCurrent evidenceCare needsHIVGreater burdenEconomic statusIndustrialised worldPreventionAIDS pandemicGlobal perspectiveHealthcare servicesLess accessTime of introductionAvailability of resourcesDemographic effectsDiminished rateSexCountriesWorld
1996
Invasive Pneumococcal Disease: Clinical Features, Serotypes, and Antimicrobial Resistance Patterns in Cases Involving Patients with and Without Human Immunodeficiency Virus Infection
Frankel R, Virata M, Hardalo C, Altice F, Friedland G. Invasive Pneumococcal Disease: Clinical Features, Serotypes, and Antimicrobial Resistance Patterns in Cases Involving Patients with and Without Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 1996, 23: 577-584. PMID: 8879783, DOI: 10.1093/clinids/23.3.577.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseasePneumococcal diseaseClinical featuresPenicillin-resistant pneumococcal infectionsHuman immunodeficiency virus (HIV) diseaseHuman immunodeficiency virus (HIV) infectionCommon capsular typesSource of bacteremiaImmunodeficiency virus infectionOverall mortality rateAntibiotic susceptibility patternPolyvalent pneumococcal vaccineType 9VCommon risk factorsPenicillin-resistant isolatesAntimicrobial resistance patternsPneumococcal infectionPneumococcal vaccineHIV infectionHIV serostatusHIV statusRecurrence rateInvasive diseaseRisk factorsSusceptibility patternsA prospective study of syphilis and HIV infection among injection drug users receiving methadone in the Bronx, NY.
Gourevitch M, Hartel D, Schoenbaum E, Selwyn P, Davenny K, Friedland G, Klein R. A prospective study of syphilis and HIV infection among injection drug users receiving methadone in the Bronx, NY. American Journal Of Public Health 1996, 86: 1112-5. PMID: 8712270, PMCID: PMC1380622, DOI: 10.2105/ajph.86.8_pt_1.1112.Peer-Reviewed Original ResearchConceptsInjection drug usersHIV-seronegative patientsHIV-seropositive patientsDrug usersHIV infectionEarly syphilisProspective studyHuman immunodeficiency virus (HIV) infectionHigh-risk sexual activityPercent of HIVImmunodeficiency virus infectionMethadone maintenance treatmentDrug-using womenMultiple sex partnersDiagnosis of syphilisEarly syphilis incidenceFemale drug usersHIV seroconversionHIV seroconvertersMaintenance treatmentIncidence rateIndependent riskVirus infectionSyphilis incidencePatients
1995
Injection Drug Use and Human Immunodeficiency Virus Infection
Alcabes P, Friedland G. Injection Drug Use and Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 1995, 20: 1467-1479. PMID: 7548494, DOI: 10.1093/clinids/20.6.1467.Peer-Reviewed Original ResearchConceptsSurveillance case definitionHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionDrug usersCase definitionInjection drugsVirus infectionPrevention (CDC) surveillance case definitionDiagnosis of AIDSInjection drug useInjection drug usersHigh mortality rateHIV diseaseHIV infectionDrug injectorsMortality rateDrug useNew casesNatural historyDisease controlAIDSDiagnostic facilitiesAIDS epidemicInitial epidemicLack of advocates
1994
Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users
Alcabes P, Muñoz A, Vlahov D, Friedland G. Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users. Annals Of Epidemiology 1994, 4: 17-26. PMID: 7911376, DOI: 10.1016/1047-2797(94)90038-8.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeBaltimoreCD4-Positive T-LymphocytesCohort StudiesConfidence IntervalsHIV InfectionsHIV SeroprevalenceHomosexualityHumansIncidenceLeukocyte CountLife TablesMaleModels, StatisticalNew York CityPlatelet CountRegression AnalysisSubstance Abuse, IntravenousSurvival RateTime FactorsConceptsHIV infectionDrug usersImmunodeficiency syndromeMedian timeCombined cohortHomosexual menHuman immunodeficiency virus (HIV) infectionHuman immunodeficiency virus (HIV) epidemicPercent of CD4Immunodeficiency virus infectionIncident HIV infectionProduct-limit methodMarkers of maturityHIV incubation distributionsPlatelet countVirus infectionLarge cohortSeroconversionCohortInfectionConfidence intervalsIncubation distributionAIDSVirus epidemicPopulation groups